Feb 2, 2024 • 4:01 pm EST Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Jan 26, 2024 • 7:30 am EST CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
Jan 23, 2024 • 8:00 am EST Phase 1 Clinical Data for SYS6002 (CRB-701) to be presented at 2024 ASCO GU
Jan 9, 2024 • 8:00 am EST Corbus Pharmaceuticals Announces FDA Clearance of IND Application for its anti-αvβ8 monoclonal antibody (CRB-601)
Dec 18, 2023 • 8:00 am EST Corbus Pharmaceuticals Announces Abstract Accepted for Presentation at 2024 ASCO GU
Nov 7, 2023 • 8:00 am EST Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 2, 2023 • 8:00 am EDT Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
Oct 17, 2023 • 8:00 am EDT Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023